A Single Center, Open-label Study to Determine the Safety and Efficacy of a Dosing Regimen of Eculizumab Added to Conventional Treatment in the Prevention of Antibody-mediated Rejection (AMR) in Positive Crossmatch Living Donor Kidney Transplantation

Trial Profile

A Single Center, Open-label Study to Determine the Safety and Efficacy of a Dosing Regimen of Eculizumab Added to Conventional Treatment in the Prevention of Antibody-mediated Rejection (AMR) in Positive Crossmatch Living Donor Kidney Transplantation

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Jun 2015 Planned End Date changed from 1 Aug 2015 to 1 Aug 2017 as reported by ClinicalTrials.gov record.
    • 06 Jun 2015 Planned primary completion date changed from 1 May 2014 to 1 May 2017 as reported by ClinicalTrials.gov record.
    • 30 Jan 2015 Primary endpoint has not been met. (Efficacy of eculizumab in preventing AMR in positive crossmatch patients undergoing +XMatch LDKTx. at 6 months, as reported by Alexion Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top